Showing papers by "Cora N. Sternberg published in 1997"
TL;DR: Adjuvant treatment with goserelin, when started simultaneously with external irradiation, improves local control and survival in patients with locally advanced prostate cancer.
Abstract: Background We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces testosterone secretion) in patients with locally advanced prostate cancer. Methods From 1987 to 1995, 415 patients with locally advanced prostate cancer were randomly assigned to receive radiotherapy alone or radiotherapy plus immediate treatment with goserelin. The patients had a median age of 71 years (range, 51 to 80). Patients in both groups received 50 Gy of radiation to the pelvis over a period of five weeks and an additional 20 Gy over an additional two weeks as a prostatic boost. Patients in the combined-treatment group received 3.6 mg of goserelin (Zoladex) subcutaneously every four weeks starting on the first day of irradiation and continuing for three years; those patients also received cyproterone acetate (150 mg orally per day) during the first month of treatment to inhibit the transient rise in test...
1,450 citations
TL;DR: The Bard BTA test is a noninvasive test that may be an important addition to cystoscopy and cytology in the routine surveillance of patients with a history of transitional cell cancer of the bladder.
51 citations
TL;DR: A favorable toxicity profile and similar efficacy to cisplatin stimulated a phase II study in patients with advanced urothelial tract tumors.
20 citations
Journal Article•
3 citations
TL;DR: In this paper, a review of the various therapeutic options available to patients with locally invasive bladder cancer is presented, including neoadjuvant and adjuvant chemotherapy, in combination with primary treatment.
Abstract: Radical cystectomy has traditionally been considered the gold standard of treatment for patients with muscle-invasive bladder cancer. Following cystectomy a significant portion of patients will develop systemic relapse, usually within 2 to 3 years. Several randomized trials of neoadjuvant and adjuvant chemotherapy suggest that chemotherapy used in combination with primary treatment may improve disease-free survival and permit bladder preservation in selected cases. Whether or not neoadjuvant and adjuvant chemotherapy influence long-term survival remains controversial. This article reviews in depth the various therapeutic options available to patients with locally invasive bladder cancer.